Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05329103 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by Peel Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
65
Enrollment target
7
Study locations

NCT05329103 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Peel Therapeutics. The registered enrollment target is 65 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (66% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05329103, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Peel Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
65 participants
Enrollment target
7
Study locations

Study Summary

This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG PEEL-224
  • DRUG FOLF+B

Study Locations (7)

Arizona

  • HonorHealth Research Institiute - Scottsdale

California

  • Stanford Cancer Center - Palo Alto

North Carolina

  • Carolina BioOncology Institute - Huntersville

Pennsylvania

  • Abramson Cancer Center at Pennsylvania Hospital - Philadelphia

Texas

  • Mary Crowley Cancer Research - Dallas

Utah

  • Huntsman Cancer Institute, University of Utah - Salt Lake City

Virginia

  • NEXT Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2022-07-11
Est. Completion 2026-03
Phase Phase 1

Sponsor

Peel Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05329103

The ClinicalTrials.gov registry entry for NCT05329103 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (66% lower). The listed sponsor is Peel Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which PEEL-224 is the first listed.

NCT05329103 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT05329103 about?

NCT05329103 is a clinical study titled "A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors". This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.

What is the current status of trial NCT05329103?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2022-07-11. Estimated completion is 2026-03.

What conditions does trial NCT05329103 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT05329103?

The interventions under investigation include: PEEL-224 (DRUG), FOLF+B (DRUG).

Who is sponsoring clinical trial NCT05329103?

This trial is sponsored by Peel Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05329103 being conducted?

This trial has 7 study locations across Arizona, California, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.